ReviewFrontiers in immunology2022
The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Genetically proxied gut microbiota and cancer risk: a scoping review of Mendelian randomization studies.Archives of public health = Archives belges de sante publique · 2025Pooled it
- Intratumoral microbiota in colorectal cancer: roles, therapeutic potential, and challenges.Journal of advanced research · 2026Review
- Review
- Article
- Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review.Clinical and experimental medicine · 2026Review
- Integrative analysis identifies the intratumoral Fusobacterium nucleatum as a driver of cervical cancer malignancy.BMC biotechnology · 2026Article
- Microbial medicines: Unlocking the therapeutic potential of the microbiome in cancer treatment.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Deciphering the intratumor microbiota in malignant gastrointestinal tumors: multifaceted interplay and clinical implications.Cell communication and signaling : CCS · 2026Review
- The intratumoral microbiome: a review of the tumor microenvironment's fourth axis shaping anti-tumor immunity, cancer prognosis, and therapeutic response.Frontiers in immunology · 2026Review
- The role of the intratumoral microbiota in breast cancer metastasis and immune regulation: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- Gut-Liver Microbiome and Tumor Microenvironment in Metabolic Dysfunction-Associated Steatotic Liver Disease.Advances in experimental medicine and biology · 2026Review
- Harnessing Next-Generation 3D Cancer Models to Elucidate Tumor-Microbiome Crosstalk.Advanced healthcare materials · 2026Review
- Intratumorally specific microbial-derived lipopolysaccharide contributes to non-small cell lung cancer progression.Virulence · 2025Article
- Intratumoral microbiome is associated with the response to cancer immunotherapy in lung cancer patients with high PD-L1 expression.Immuno-oncology technology · 2025Article
- Tumor-associated microbiota: Multi-cancer landscape, mechanistic insights and clinical translation (Review).Oncology letters · 2025Review
- Comparative microbiome profiling reveals unique signatures in multiple primary lung cancers.Translational cancer research · 2025Article
- Integrated multi-omic analysis unravels the characteristics of the metabolism-related intratumoral microbes and establishes a novel signature for predicting prognosis and therapeutic response in lung adenocarcinoma.Translational cancer research · 2025Article
- The role and challenges of intratumoral microbiota in colorectal cancer immunotherapy.Frontiers in pharmacology · 2025Review
- Microbial infection and treatment strategies in cancer patients.Frontiers in microbiology · 2025Review
- The microbial conductor of cancer hallmarks: intratumoral microbiome as a multidimensional oncogenic modulator.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past few decades, great progress has been achieved in the understanding of microbiome-cancer interactions. However, most of the studies have focused on the gut microbiome, ignoring how other microbiomes interact with tumors. Emerging evidence suggests that in many types of cancers, such as lung cancer, pancreatic cancer, and colorectal cancer, the intratumoral microbiome plays a significant role. In addition, accumulating evidence suggests that intratumoral microbes have multiple effects on the biological behavior of tumors, for example, regulating tumor initiation and progression and altering the tumor response to chemotherapy and immunotherapy. However, to fully understand the role of the intratumoral microbiome in cancer, further investigation of the effects and mechanisms is still needed. This review discusses the role of intratumoral bacteria in tumorigenesis and tumor progression, recurrence and metastasis, as well as their effect on cancer prognosis and treatment outcome, and summarizes the relevant mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.